Posted by Michael Wonder on 20 Sep 2022
Cidara Therapeutics announces FDA acceptance for priority review of new drug application for rezafungin for the treatment of candidemia and invasive candidiasis
20 September 2022 - Assigned PDUFA target action date of 22 March 2023.
Cidara Therapeutics today announced that the US FDA has accepted for filing and granted Priority Review to its new drug application for rezafungin for the treatment of candidemia and invasive candidiasis.
